Clinical Trial Results:
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Summary
|
|
EudraCT number |
2010-022782-99 |
Trial protocol |
FR DE DK IT ES |
Global end of trial date |
17 Oct 2012
|
Results information
|
|
Results version number |
v1 |
This version publication date |
15 Jul 2016
|
First version publication date |
08 Aug 2015
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GA00887 (Q4881g)
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01287117 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
F. Hoffmann-La Roche AG
|
||
Sponsor organisation address |
Grenzacherstrasse 124., Basel, Switzerland, CH-4070
|
||
Public contact |
Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
|
||
Scientific contact |
Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Oct 2012
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Oct 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
This was a global, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult participants aged 12 to 75 years who have been diagnosed with refractory CIU and who remain symptomatic despite standard dosed H1 antihistamine treatment.
|
||
Protection of trial subjects |
This study was conducted in accordance with the U.S. Food and Drug Administration (FDA) regulations, the International Conference on Harmonisation (ICH) E6 Guideline for Good Clinical Practice (GCP), Declaration of Helsinki, and applicable local, state, and federal laws, as well as other applicable country laws. The Clinical Study Protocol (CSP) and the Informed Consent Forms (ICFs) were reviewed and approved by an Independent Ethics Committee (IEC).
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
16 Feb 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 17
|
||
Country: Number of subjects enrolled |
France: 9
|
||
Country: Number of subjects enrolled |
Germany: 26
|
||
Country: Number of subjects enrolled |
Italy: 2
|
||
Country: Number of subjects enrolled |
Poland: 39
|
||
Country: Number of subjects enrolled |
Turkey: 2
|
||
Country: Number of subjects enrolled |
United States: 220
|
||
Country: Number of subjects enrolled |
Spain: 4
|
||
Worldwide total number of subjects |
319
|
||
EEA total number of subjects |
97
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
18
|
||
Adults (18-64 years) |
285
|
||
From 65 to 84 years |
16
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
Randomized population: All randomized participants regardless of whether they received any study drug. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants received placebo subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for cutaneous solution
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Participants received placebo administered by SC injection every 4 weeks during the 24-week double-blind treatment period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Omalizumab 75 mg | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants received omalizumab 75 milligrams (mg) subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Omalizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for cutaneous solution
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Participants received SC omalizumab at doses of 75, 150, or 300 mg every 4 weeks during the 24-week, double-blind treatment period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Omalizumab 150 mg | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Omalizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for cutaneous solution
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Participants received SC omalizumab at doses of 75, 150, or 300 mg every 4 weeks during the 24-week, double-blind treatment period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Omalizumab 300 mg | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Omalizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for cutaneous solution
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Participants received SC omalizumab at doses of 75, 150, or 300 mg every 4 weeks during the 24-week, double-blind treatment period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Omalizumab 75 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received omalizumab 75 milligrams (mg) subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Omalizumab 150 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Omalizumab 300 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants received placebo subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||
Reporting group title |
Omalizumab 75 mg
|
||
Reporting group description |
Participants received omalizumab 75 milligrams (mg) subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||
Reporting group title |
Omalizumab 150 mg
|
||
Reporting group description |
Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24-week double-blind treatment period. | ||
Reporting group title |
Omalizumab 300 mg
|
||
Reporting group description |
Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24-week double-blind treatment period. |
|
||||||||||||||||||||||||||
End point title |
Change From Baseline to Week 12 in the Weekly Itch Severity Score | |||||||||||||||||||||||||
End point description |
The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
|||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Statistical analysis title |
Change From Baseline to Week 12 in the Weekly Itch | |||||||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups.
|
|||||||||||||||||||||||||
Comparison groups |
Omalizumab 75 mg v Placebo
|
|||||||||||||||||||||||||
Number of subjects included in analysis |
157
|
|||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||
Analysis type |
superiority [1] | |||||||||||||||||||||||||
P-value |
= 0.001 [2] | |||||||||||||||||||||||||
Method |
ANCOVA | |||||||||||||||||||||||||
Parameter type |
Least squares mean difference | |||||||||||||||||||||||||
Point estimate |
-2.96
|
|||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||
lower limit |
-4.71 | |||||||||||||||||||||||||
upper limit |
-1.21 | |||||||||||||||||||||||||
Notes [1] - Covariates included in the analysis were baseline weekly itch severity score (less than [<] 13 verses [vs] ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [2] - A multiplicity type I error control plan was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided). |
||||||||||||||||||||||||||
Statistical analysis title |
Change From Baseline to Week 12 in the Weekly Itch | |||||||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
|||||||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
|||||||||||||||||||||||||
Number of subjects included in analysis |
160
|
|||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||
Analysis type |
superiority [3] | |||||||||||||||||||||||||
P-value |
= 0.0012 [4] | |||||||||||||||||||||||||
Method |
ANCOVA | |||||||||||||||||||||||||
Parameter type |
Least squares mean difference | |||||||||||||||||||||||||
Point estimate |
-2.95
|
|||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||
lower limit |
-4.72 | |||||||||||||||||||||||||
upper limit |
-1.18 | |||||||||||||||||||||||||
Notes [3] - Covariates included in the analysis were baseline weekly itch severity score (<13 vs ≥13) and baseline weight (<80 kg vs ≥80 kg). [4] - A multiplicity type I error control plan was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided). |
||||||||||||||||||||||||||
Statistical analysis title |
Change From Baseline to Week 12 in the Weekly Itch | |||||||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
|||||||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
|||||||||||||||||||||||||
Number of subjects included in analysis |
161
|
|||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||
Analysis type |
superiority [5] | |||||||||||||||||||||||||
P-value |
= 0.0001 [6] | |||||||||||||||||||||||||
Method |
ANCOVA | |||||||||||||||||||||||||
Parameter type |
Least squares mean difference | |||||||||||||||||||||||||
Point estimate |
-5.8
|
|||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||
lower limit |
-7.49 | |||||||||||||||||||||||||
upper limit |
-4.1 | |||||||||||||||||||||||||
Notes [5] - Covariates included in the analysis were baseline weekly itch severity score (<13 vs ≥13) and baseline weight (<80 kg vs ≥80 kg). [6] - A multiplicity type I error control plan was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided). |
|
||||||||||||||||||||||||||
End point title |
Change From Baseline to Week 12 in the Urticaria Activity Score Over 7 Days (UAS7) | |||||||||||||||||||||||||
End point description |
The UAS7 is the sum of the daily urticarial activity scores over 7 days and ranges from 0 to 42. The daily urticarial activity score is the average of the morning and evening urticarial activity scores and ranges from 0 to 6. The urticarial activity score is the sum of ratings on a scale of 0 to 3 (0 is equal to [=] none to 3 = intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticarial activity scores over the 7 days prior to the first treatment. A higher urticarial activity score indicates more urticaria activity. A negative change score indicates improvement. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
|||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Statistical analysis title |
Change From Baseline to Week 12 in the UAS7 | |||||||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups.
|
|||||||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
|||||||||||||||||||||||||
Number of subjects included in analysis |
157
|
|||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||
Analysis type |
superiority [7] | |||||||||||||||||||||||||
P-value |
= 0.0035 [8] | |||||||||||||||||||||||||
Method |
ANCOVA | |||||||||||||||||||||||||
Parameter type |
Least squares mean difference | |||||||||||||||||||||||||
Point estimate |
-5.75
|
|||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||
lower limit |
-9.59 | |||||||||||||||||||||||||
upper limit |
-1.92 | |||||||||||||||||||||||||
Notes [7] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [8] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
||||||||||||||||||||||||||
Statistical analysis title |
Change From Baseline to Week 12 in the UAS7 | |||||||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
|||||||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
|||||||||||||||||||||||||
Number of subjects included in analysis |
160
|
|||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||
Analysis type |
superiority [9] | |||||||||||||||||||||||||
P-value |
= 0.0008 [10] | |||||||||||||||||||||||||
Method |
ANCOVA | |||||||||||||||||||||||||
Parameter type |
Least squares mean difference | |||||||||||||||||||||||||
Point estimate |
-6.54
|
|||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||
lower limit |
-10.33 | |||||||||||||||||||||||||
upper limit |
-2.75 | |||||||||||||||||||||||||
Notes [9] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [10] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
||||||||||||||||||||||||||
Statistical analysis title |
Change From Baseline to Week 12 in the UAS7 | |||||||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
|||||||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
|||||||||||||||||||||||||
Number of subjects included in analysis |
161
|
|||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||
Analysis type |
superiority [11] | |||||||||||||||||||||||||
P-value |
= 0.0001 [12] | |||||||||||||||||||||||||
Method |
ANCOVA | |||||||||||||||||||||||||
Parameter type |
Least squares mean difference | |||||||||||||||||||||||||
Point estimate |
-12.8
|
|||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||
level |
95% | |||||||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||||||
lower limit |
-16.44 | |||||||||||||||||||||||||
upper limit |
-9.16 | |||||||||||||||||||||||||
Notes [11] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [12] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Change From Baseline to Week 12 in the Weekly Number of Hives Score | ||||||||||||||||||||
End point description |
The weekly hives score is the sum of the daily hives scores over 7 days and ranges from 0 to 21. The number of hives is measured twice daily (morning and evening) on a scale of 0 (none) to 3 (> 12 hives per 12 hours). The daily hives score is the average of the morning and evening scores. The Baseline score is the sum of the daily hives scores over the 7 days prior to the first treatment. A higher score indicates more hives. A negative change score indicates improvement. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in Hives Score at Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [13] | ||||||||||||||||||||
P-value |
= 0.0149 [14] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-2.75
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-4.95 | ||||||||||||||||||||
upper limit |
-0.54 | ||||||||||||||||||||
Notes [13] - Covariates included in the analysis were baseline weekly number of hives score (< median vs ≥ median) and baseline weight (< 80 kg vs ≥ 80 kg). [14] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in Hives Score at Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
160
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [15] | ||||||||||||||||||||
P-value |
= 0.0017 [16] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-3.44
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-5.57 | ||||||||||||||||||||
upper limit |
-1.32 | ||||||||||||||||||||
Notes [15] - Covariates included in the analysis were baseline weekly number of hives score (< median vs ≥ median) and baseline weight (< 80 kg vs ≥ 80 kg). [16] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in Hives Score at Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [17] | ||||||||||||||||||||
P-value |
< 0.0001 [18] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-6.93
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-9.1 | ||||||||||||||||||||
upper limit |
-4.76 | ||||||||||||||||||||
Notes [17] - Covariates included in the analysis were baseline weekly number of hives score (< median vs ≥ median) and baseline weight (< 80 kg vs ≥ 80 kg). [18] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | ||||||||||||||||||||
End point description |
The time to the MID response is the number of weeks from the start of treatment (Baseline) until the time point at which the first MID response occurs. The MID response is defined as a reduction ≥ 5 points from Baseline in the weekly itch severity score. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Time to MID Response in Weekly Itch Severity Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
114
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [19] | ||||||||||||||||||||
P-value |
= 0.0879 [20] | ||||||||||||||||||||
Method |
Cox proportional hazards model | ||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||||
Point estimate |
1.39
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
0.95 | ||||||||||||||||||||
upper limit |
2.03 | ||||||||||||||||||||
Notes [19] - Covariates included in the analysis were baseline weekly itch severity score (< 13 vs ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [20] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Time to MID Response in Weekly Itch Severity Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
123
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [21] | ||||||||||||||||||||
P-value |
= 0.0301 [22] | ||||||||||||||||||||
Method |
Cox proportional hazards model | ||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||||
Point estimate |
1.49
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
1.04 | ||||||||||||||||||||
upper limit |
2.14 | ||||||||||||||||||||
Notes [21] - Covariates included in the analysis were baseline weekly itch severity score (< 13 vs ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [22] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Time to MID Response in Weekly Itch Severity Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [23] | ||||||||||||||||||||
P-value |
< 0.0001 [24] | ||||||||||||||||||||
Method |
Cox proportional hazards model | ||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||||
Point estimate |
2.34
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
1.63 | ||||||||||||||||||||
upper limit |
3.36 | ||||||||||||||||||||
Notes [23] - Covariates included in the analysis were baseline weekly itch severity score (< 13 vs ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [24] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Percentage of Participants With a UAS7 Score ≤ 6 at Week 12 | ||||||||||||||||||||
End point description |
The UAS7 is the sum of the daily urticarial activity scores over 7 days and ranges from 0 to 42. The daily urticarial activity score is the average of the morning and evening urticarial activity scores and ranges from 0 to 6. The urticarial activity score is the sum of ratings on a scale of 0 to 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticarial activity scores over the 7 days prior to the first treatment. A higher urticarial activity score indicates more urticaria activity. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Percentage of Participants With a UAS7 Score ≤6 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [25] | ||||||||||||||||||||
P-value |
= 0.0148 [26] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [25] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (< 80 kg vs ≥ 80 kg). [26] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Percentage of Participants With a UAS7 Score ≤6 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
160
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [27] | ||||||||||||||||||||
P-value |
< 0.0001 [28] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [27] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (< 80 kg vs ≥ 80 kg). [28] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Percentage of Participants With a UAS7 Score ≤6 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [29] | ||||||||||||||||||||
P-value |
< 0.0001 [30] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [29] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (< 80 kg vs ≥ 80 kg). [30] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Percentage of Weekly Itch Severity Score MID Responders at Week 12 | ||||||||||||||||||||
End point description |
The percentage of participants with an itch severity score at 12 Weeks at least 5 points lower than at Baseline. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
% of Weekly Itch Severity Score MID Responders | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [31] | ||||||||||||||||||||
P-value |
= 0.0118 [32] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [31] - Covariates included in the analysis were baseline weekly itch severity score (< 13 vs ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [32] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
% of Weekly Itch Severity Score MID Responders | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
160
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [33] | ||||||||||||||||||||
P-value |
= 0.0226 [34] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [33] - Covariates included in the analysis were baseline weekly itch severity score (< 13 vs ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [34] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
% of Weekly Itch Severity Score MID Responders | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [35] | ||||||||||||||||||||
P-value |
< 0.0001 [36] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [35] - Covariates included in the analysis were baseline weekly itch severity score (< 13 vs ≥ 13) and baseline weight (< 80 kg vs ≥ 80 kg). [36] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Change From Baseline to Week 12 in the Weekly Size of the Largest Hive Score | ||||||||||||||||||||
End point description |
The weekly size of the largest hive score is the sum of the daily size of the largest hive scores over 7 days and ranges from 0 to 21. The daily size of the largest hive score is assessed twice daily (morning and evening) on a scale of 0 (none) to 3 (> 2.5 cm). The daily size of the largest hive score is the average of the morning and evening scores. The Baseline weekly size of the largest hive score is calculated over the 7 days prior to the first treatment. A higher score indicates larger hives. A negative change score indicates a reduction in hive size. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in Largest Hive Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [37] | ||||||||||||||||||||
P-value |
= 0.0124 [38] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-2.34
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-4.17 | ||||||||||||||||||||
upper limit |
-0.51 | ||||||||||||||||||||
Notes [37] - Covariates included in the analysis were baseline weekly size of largest hive score (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [38] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in Largest Hive Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
160
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [39] | ||||||||||||||||||||
P-value |
= 0.0012 [40] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-3.16
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-5.05 | ||||||||||||||||||||
upper limit |
-1.27 | ||||||||||||||||||||
Notes [39] - Covariates included in the analysis were baseline weekly size of largest hive score (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [40] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in Largest Hive Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [41] | ||||||||||||||||||||
P-value |
< 0.0001 [42] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-5.73
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-7.59 | ||||||||||||||||||||
upper limit |
-3.87 | ||||||||||||||||||||
Notes [41] - Covariates included in the analysis were baseline weekly size of largest hive score (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [42] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12 | ||||||||||||||||||||
End point description |
The DLQI is a 10-item dermatology-specific health-related quality of life measure. Participants rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives on a scale of 0 (Not at all) to 3 (Very much). The overall DLQI is the sum of the responses to the 10 items and ranges from 0 to 30. A lower score indicates a better quality of life. A negative change score indicates improvement.mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline to Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Notes [43] - n (number) = participants with values at both Baseline and Week 12 were included in the analysis. [44] - n (number) = participants with values at both Baseline and Week 12 were included in the analysis. [45] - n (number) = participants with values at both Baseline and Week 12 were included in the analysis. [46] - n (number) = participants with values at both Baseline and Week 12 were included in the analysis. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in the Overall DLQI Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
128
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [47] | ||||||||||||||||||||
P-value |
= 0.7956 [48] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
0.26
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-1.76 | ||||||||||||||||||||
upper limit |
2.28 | ||||||||||||||||||||
Notes [47] - Covariates included in the analysis were baseline overall DLQI score (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [48] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in the Overall DLQI Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
125
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [49] | ||||||||||||||||||||
P-value |
= 0.2286 [50] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-1.31
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-3.46 | ||||||||||||||||||||
upper limit |
0.84 | ||||||||||||||||||||
Notes [49] - Covariates included in the analysis were baseline overall DLQI score (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [50] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
Change From Baseline in the Overall DLQI Score | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
134
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [51] | ||||||||||||||||||||
P-value |
< 0.0001 [52] | ||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||
Parameter type |
Least squares mean difference | ||||||||||||||||||||
Point estimate |
-4.08
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-5.96 | ||||||||||||||||||||
upper limit |
-2.2 | ||||||||||||||||||||
Notes [51] - Covariates included in the analysis were baseline overall DLQI score (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [52] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Percentage of Angioedema-free Days From Week 4 to Week 12 | ||||||||||||||||||||
End point description |
The percentage of angioedema-free days from Weeks 4 to 12 was defined as the number of days for which a participant responded “No” to the angioedema question in the daily diary divided by the total number of days with a non-missing diary entry, starting at the Week 4 visit and ending the day prior to the Week 12 visit. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 4 to Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Notes [53] - n (number) = participants with nonmissing values at Week 4 and Week 12 were included in the analysis [54] - n (number) = participants with nonmissing values at Week 4 and Week 12 were included in the analysis [55] - n (number) = participants with nonmissing values at Week 4 and Week 12 were included in the analysis [56] - n (number) = participants with nonmissing values at Week 4 and Week 12 were included in the analysis |
|||||||||||||||||||||
Statistical analysis title |
% of Angioedema-free Days From Week 4 to Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
135
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [57] | ||||||||||||||||||||
P-value |
= 0.4867 [58] | ||||||||||||||||||||
Method |
Stratified Wilcoxon | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [57] - Stratification variables included in the analysis were presence of angioedema at baseline (yes vs no) and baseline weight (< 80 kg vs ≥ 80 kg). [58] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
% of Angioedema-free Days From Week 4 to Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate
control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
136
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [59] | ||||||||||||||||||||
P-value |
= 0.1747 [60] | ||||||||||||||||||||
Method |
Stratified Wilcoxon | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [59] - Stratification variables included in the analysis were presence of angioedema at baseline (yes vs no) and baseline weight (< 80 kg vs ≥ 80 kg). [60] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
% of Angioedema-free Days From Week 4 to Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate
control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
140
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [61] | ||||||||||||||||||||
P-value |
< 0.0001 [62] | ||||||||||||||||||||
Method |
Stratified Wilcoxon | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [61] - Stratification variables included in the analysis were presence of angioedema at baseline (yes vs no) and baseline weight (< 80 kg vs ≥ 80 kg). [62] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
|||||||||||||||||||||
End point title |
Percentage of Complete Responders (UAS7 = 0) at Week 12 | ||||||||||||||||||||
End point description |
A complete responder was defined as a participant with a UAS7 score = 0 at Week 12. mITT Population: All randomized participants who received at least 1 dose of study drug.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
% of Complete Responders (UAS7 = 0) at Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 75 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 75 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [63] | ||||||||||||||||||||
P-value |
= 0.458 [64] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [63] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [64] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
% of Complete Responders (UAS7 = 0) at Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 150 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 150 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
160
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [65] | ||||||||||||||||||||
P-value |
= 0.2087 [66] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [65] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [66] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|||||||||||||||||||||
Statistical analysis title |
% of Complete Responders (UAS7 = 0) at Week 12 | ||||||||||||||||||||
Statistical analysis description |
The null hypothesis was that there was no difference between the placebo and the omalizumab 300 mg groups. The p-value was not evaluated for statistical significance in accordance with the type I error rate control plan.
|
||||||||||||||||||||
Comparison groups |
Placebo v Omalizumab 300 mg
|
||||||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority [67] | ||||||||||||||||||||
P-value |
< 0.0001 [68] | ||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [67] - Covariates included in the analysis were baseline UAS7 (< median vs ≥ median) and baseline weight (<80 kg vs ≥80 kg). [68] - A pre-specified hierarchical order of testing was employed to adjust for the comparison of multiple omalizumab groups to the placebo group in order to maintain an overall type I error rate of 0.05 (2-sided) within each dose. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were reported starting with the first dose of study drug through the end of the study (up to 40 weeks).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety population: All randomized participants who received at least 1 dose of study drug.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Omalizumab 75 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Omalizumab 150 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Omalizumab 300 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 Jan 2011 |
• The number of weeks that a participant must have had chronic idiopathic urticaria (CIU) symptoms despite being on H1 antihistamines was increased from 6 to 8 weeks.
• The secondary objectives were clarified to indicate that a goal of this study was to provide information regarding the recurrence of disease/symptoms after withdrawal of omalizumab in participants with refractory CIU. Secondary and exploratory endpoints were modified as a result.
• Procedures regarding the use of excluded therapy were modified in an effort to continue to follow participants for safety evaluation after they had discontinued study drug treatment.
• The washout period required after regular doxepin use prior to enrollment was reduced from 6 weeks to 14 days.
• The criterion for women of childbearing potential and pregnancy was clarified. Additionally, nursing women were excluded from study participation.
• Contraindications to diphenydramine were added.
• The in-clinic urticaria activity score terminology was corrected.
• The start of the screening period was modified from 14−18 to 12−18 days prior to Day 1.
• The difference between discontinuation from study treatment and discontinuation from the study was clarified.
• The Medical Monitor was replaced. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |